| abstract |
Referring to an anticancer agent comprising a cyclized tumor targeting peptide, of formula I, having an arsenic atom attached to two cysteine residues, said cysteine residues are separated by less than 20 amino acid residues (curved line); R is a stabilizing group attached to the arsenic atom, wherein the stabilizing group is selected from the group consisting of hydroxyl, C1 to C6 alkyl, C2 to C6 alkenyl, aryl, etc. Said cyclized tumor targeting peptide comprises at least one arginine or lysine residue. It also refers to a pharmaceutical composition, a process for producing said anticancer agent, and an in vitro method for the diagnosis of cancer. |